SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI5/9/2007 12:22:41 PM
   of 3044
 
From HGSI's earnings PR today...

...
The Journal of Clinical Oncology published the results of the first human
study of HGS-ETR1 in April 2007, along with a positive editorial. At the
Annual Meeting of the American Association of Cancer Research (AACR 2007) in
April, approximately 1500 cancer scientists and researchers attended a review
of TRAIL receptor antibody research presented by an HGS scientist. A separate
poster presentation reported the results of a preclinical study, which
demonstrated that low concentrations of Velcade (bortezomib) can be used to
sensitize certain non-small cell lung cancer cell lines that are resistant to
killing by TRAIL receptor-activated apoptosis, making it possible for HGS-ETR1
or HGS-ETR2 to activate cell death.

HGS believes that HGS-ETR1 and HGS-ETR2 could offer novel, highly targeted
therapeutic options that may prove useful in the treatment of a number of
cancers.
...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News